Stigma in drug research holding back new therapies
October 10, 2022 DOI: 10.54377/4346-4c8c (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Topics | Cannabis MDMA Psilocybin |
| Keywords | Hallucinogen Mental health Mental illness Drug Stigma botany |
| Key points | Argues that while party drugs like ketamine and psychedelics are being considered for mental health therapies, proper clinical trials should not be abandoned. |
Abstract
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new therapies for mental illness were previously considered unthinkable — party drugs including ketamine, medicinal cannabis and psychedelics like MDMA, psilocybin and DMT. With mental health disorders a growing cause of disability […]
Comparable studies
Other theoretical and historical papers on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Delta-8, Delta-10, HHC, THC-O, THCP, and THCV: What Should We Call These Products? | 2023 | Theoretical or philosophical paper | |
| Model Psychoses Induced by LSD-25 in Normals | 1956 | Historical analysis | |
| Is there a specific ‘cannabis psychosis’? | 2004 | Theoretical or philosophical paper | |
| Peak-experience and the entheogenic use of cannabis in world religions | 2021 | Theoretical or philosophical paper | |
| Out of Harm's Way?: Illicit Drug Use, Medicalization and the Law | 2003 | Theoretical or philosophical paper |